nodes	percent_of_prediction	percent_of_DWPC	metapath
Ranitidine—SLC22A1—Cytarabine—lymphatic system cancer	0.193	0.258	CbGbCtD
Ranitidine—CYP1A2—Carmustine—lymphatic system cancer	0.0991	0.132	CbGbCtD
Ranitidine—CYP3A5—Teniposide—lymphatic system cancer	0.0895	0.12	CbGbCtD
Ranitidine—CYP2C19—Teniposide—lymphatic system cancer	0.0722	0.0964	CbGbCtD
Ranitidine—SLC22A8—Methotrexate—lymphatic system cancer	0.0547	0.073	CbGbCtD
Ranitidine—CYP3A5—Vincristine—lymphatic system cancer	0.0431	0.0575	CbGbCtD
Ranitidine—ABCB1—Mitoxantrone—lymphatic system cancer	0.0407	0.0544	CbGbCtD
Ranitidine—CYP3A4—Cytarabine—lymphatic system cancer	0.0354	0.0473	CbGbCtD
Ranitidine—CYP3A4—Teniposide—lymphatic system cancer	0.0349	0.0466	CbGbCtD
Ranitidine—ABCB1—Vincristine—lymphatic system cancer	0.028	0.0374	CbGbCtD
Ranitidine—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0244	0.0326	CbGbCtD
Ranitidine—ABCB1—Methotrexate—lymphatic system cancer	0.017	0.0227	CbGbCtD
Ranitidine—CYP3A4—Vincristine—lymphatic system cancer	0.0168	0.0224	CbGbCtD
Ranitidine—Pancytopenia—Bleomycin—lymphatic system cancer	0.000912	0.00363	CcSEcCtD
Ranitidine—Liver disorder—Methotrexate—lymphatic system cancer	0.000908	0.00362	CcSEcCtD
Ranitidine—Haematemesis—Methotrexate—lymphatic system cancer	0.000891	0.00355	CcSEcCtD
Ranitidine—Chest pain—Teniposide—lymphatic system cancer	0.000884	0.00352	CcSEcCtD
Ranitidine—Cardiac arrest—Vincristine—lymphatic system cancer	0.00088	0.00351	CcSEcCtD
Ranitidine—Weight decreased—Bleomycin—lymphatic system cancer	0.000869	0.00346	CcSEcCtD
Ranitidine—Pneumonia—Bleomycin—lymphatic system cancer	0.000861	0.00343	CcSEcCtD
Ranitidine—Confusional state—Teniposide—lymphatic system cancer	0.000854	0.00341	CcSEcCtD
Ranitidine—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.000847	0.00338	CcSEcCtD
Ranitidine—Ill-defined disorder—Fludarabine—lymphatic system cancer	0.000847	0.00337	CcSEcCtD
Ranitidine—Blood creatinine increased—Mitoxantrone—lymphatic system cancer	0.000845	0.00337	CcSEcCtD
Ranitidine—Anaemia—Fludarabine—lymphatic system cancer	0.000843	0.00336	CcSEcCtD
Ranitidine—Agitation—Fludarabine—lymphatic system cancer	0.000839	0.00334	CcSEcCtD
Ranitidine—Dysphagia—Carmustine—lymphatic system cancer	0.000838	0.00334	CcSEcCtD
Ranitidine—Thrombocytopenia—Teniposide—lymphatic system cancer	0.00083	0.00331	CcSEcCtD
Ranitidine—Tachycardia—Teniposide—lymphatic system cancer	0.000827	0.0033	CcSEcCtD
Ranitidine—Abdominal pain upper—Mitoxantrone—lymphatic system cancer	0.000823	0.00328	CcSEcCtD
Ranitidine—Malaise—Fludarabine—lymphatic system cancer	0.000823	0.00328	CcSEcCtD
Ranitidine—Hyperhidrosis—Teniposide—lymphatic system cancer	0.000819	0.00327	CcSEcCtD
Ranitidine—Leukopenia—Fludarabine—lymphatic system cancer	0.000817	0.00326	CcSEcCtD
Ranitidine—Pruritus—Mechlorethamine—lymphatic system cancer	0.000813	0.00324	CcSEcCtD
Ranitidine—Pancytopenia—Carmustine—lymphatic system cancer	0.000796	0.00317	CcSEcCtD
Ranitidine—Alanine aminotransferase increased—Mitoxantrone—lymphatic system cancer	0.000795	0.00317	CcSEcCtD
Ranitidine—Hypotension—Teniposide—lymphatic system cancer	0.000792	0.00316	CcSEcCtD
Ranitidine—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.000786	0.00313	CcSEcCtD
Ranitidine—Neutropenia—Carmustine—lymphatic system cancer	0.000784	0.00312	CcSEcCtD
Ranitidine—Myalgia—Fludarabine—lymphatic system cancer	0.000777	0.0031	CcSEcCtD
Ranitidine—Arthralgia—Fludarabine—lymphatic system cancer	0.000777	0.0031	CcSEcCtD
Ranitidine—Discomfort—Fludarabine—lymphatic system cancer	0.000768	0.00306	CcSEcCtD
Ranitidine—Pancytopenia—Vincristine—lymphatic system cancer	0.00076	0.00303	CcSEcCtD
Ranitidine—Dyspnoea—Teniposide—lymphatic system cancer	0.000755	0.00301	CcSEcCtD
Ranitidine—Pneumonia—Carmustine—lymphatic system cancer	0.000752	0.003	CcSEcCtD
Ranitidine—Confusional state—Fludarabine—lymphatic system cancer	0.000751	0.00299	CcSEcCtD
Ranitidine—Neutropenia—Vincristine—lymphatic system cancer	0.000748	0.00298	CcSEcCtD
Ranitidine—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.000745	0.00297	CcSEcCtD
Ranitidine—Pancytopenia—Mitoxantrone—lymphatic system cancer	0.00074	0.00295	CcSEcCtD
Ranitidine—Erectile dysfunction—Vincristine—lymphatic system cancer	0.000737	0.00294	CcSEcCtD
Ranitidine—Vomiting—Mechlorethamine—lymphatic system cancer	0.000731	0.00291	CcSEcCtD
Ranitidine—Photosensitivity reaction—Vincristine—lymphatic system cancer	0.00073	0.00291	CcSEcCtD
Ranitidine—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.000729	0.00291	CcSEcCtD
Ranitidine—Neutropenia—Mitoxantrone—lymphatic system cancer	0.000729	0.0029	CcSEcCtD
Ranitidine—Rash—Mechlorethamine—lymphatic system cancer	0.000725	0.00289	CcSEcCtD
Ranitidine—Dermatitis—Mechlorethamine—lymphatic system cancer	0.000724	0.00289	CcSEcCtD
Ranitidine—Weight decreased—Vincristine—lymphatic system cancer	0.000724	0.00289	CcSEcCtD
Ranitidine—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00072	0.00287	CcSEcCtD
Ranitidine—Erectile dysfunction—Mitoxantrone—lymphatic system cancer	0.000718	0.00286	CcSEcCtD
Ranitidine—Pneumonia—Vincristine—lymphatic system cancer	0.000718	0.00286	CcSEcCtD
Ranitidine—Weight decreased—Mitoxantrone—lymphatic system cancer	0.000705	0.00281	CcSEcCtD
Ranitidine—Pneumonia—Mitoxantrone—lymphatic system cancer	0.000699	0.00279	CcSEcCtD
Ranitidine—Feeling abnormal—Teniposide—lymphatic system cancer	0.000698	0.00278	CcSEcCtD
Ranitidine—Sweating—Vincristine—lymphatic system cancer	0.000684	0.00273	CcSEcCtD
Ranitidine—Nausea—Mechlorethamine—lymphatic system cancer	0.000683	0.00272	CcSEcCtD
Ranitidine—Alopecia—Bleomycin—lymphatic system cancer	0.000679	0.00271	CcSEcCtD
Ranitidine—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.000679	0.0027	CcSEcCtD
Ranitidine—Jaundice—Mitoxantrone—lymphatic system cancer	0.000677	0.0027	CcSEcCtD
Ranitidine—Urticaria—Teniposide—lymphatic system cancer	0.000673	0.00268	CcSEcCtD
Ranitidine—Abdominal pain—Teniposide—lymphatic system cancer	0.00067	0.00267	CcSEcCtD
Ranitidine—Body temperature increased—Teniposide—lymphatic system cancer	0.00067	0.00267	CcSEcCtD
Ranitidine—Erythema—Bleomycin—lymphatic system cancer	0.000669	0.00267	CcSEcCtD
Ranitidine—Hallucination—Carmustine—lymphatic system cancer	0.000668	0.00266	CcSEcCtD
Ranitidine—Sweating—Mitoxantrone—lymphatic system cancer	0.000666	0.00265	CcSEcCtD
Ranitidine—Dyspnoea—Fludarabine—lymphatic system cancer	0.000664	0.00265	CcSEcCtD
Ranitidine—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.000648	0.00258	CcSEcCtD
Ranitidine—Hallucination—Vincristine—lymphatic system cancer	0.000637	0.00254	CcSEcCtD
Ranitidine—Pain—Fludarabine—lymphatic system cancer	0.000637	0.00254	CcSEcCtD
Ranitidine—Constipation—Fludarabine—lymphatic system cancer	0.000637	0.00254	CcSEcCtD
Ranitidine—Bradycardia—Mitoxantrone—lymphatic system cancer	0.000635	0.00253	CcSEcCtD
Ranitidine—Vasculitis—Methotrexate—lymphatic system cancer	0.000634	0.00253	CcSEcCtD
Ranitidine—Hypersensitivity—Teniposide—lymphatic system cancer	0.000624	0.00249	CcSEcCtD
Ranitidine—Hepatitis—Mitoxantrone—lymphatic system cancer	0.000624	0.00249	CcSEcCtD
Ranitidine—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.000621	0.00247	CcSEcCtD
Ranitidine—Anaemia—Bleomycin—lymphatic system cancer	0.000618	0.00246	CcSEcCtD
Ranitidine—Feeling abnormal—Fludarabine—lymphatic system cancer	0.000614	0.00245	CcSEcCtD
Ranitidine—Malaise—Bleomycin—lymphatic system cancer	0.000603	0.0024	CcSEcCtD
Ranitidine—Pruritus—Teniposide—lymphatic system cancer	0.0006	0.00239	CcSEcCtD
Ranitidine—Arrhythmia—Carmustine—lymphatic system cancer	0.000599	0.00239	CcSEcCtD
Ranitidine—Leukopenia—Bleomycin—lymphatic system cancer	0.000599	0.00239	CcSEcCtD
Ranitidine—Alopecia—Carmustine—lymphatic system cancer	0.000593	0.00236	CcSEcCtD
Ranitidine—Body temperature increased—Fludarabine—lymphatic system cancer	0.000589	0.00235	CcSEcCtD
Ranitidine—Erythema—Carmustine—lymphatic system cancer	0.000584	0.00233	CcSEcCtD
Ranitidine—Aplastic anaemia—Methotrexate—lymphatic system cancer	0.000581	0.00232	CcSEcCtD
Ranitidine—Diarrhoea—Teniposide—lymphatic system cancer	0.00058	0.00231	CcSEcCtD
Ranitidine—Chest pain—Bleomycin—lymphatic system cancer	0.00057	0.00227	CcSEcCtD
Ranitidine—Myalgia—Bleomycin—lymphatic system cancer	0.00057	0.00227	CcSEcCtD
Ranitidine—Alopecia—Vincristine—lymphatic system cancer	0.000566	0.00226	CcSEcCtD
Ranitidine—Discomfort—Bleomycin—lymphatic system cancer	0.000563	0.00224	CcSEcCtD
Ranitidine—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.000557	0.00222	CcSEcCtD
Ranitidine—Gynaecomastia—Methotrexate—lymphatic system cancer	0.000554	0.00221	CcSEcCtD
Ranitidine—Alopecia—Mitoxantrone—lymphatic system cancer	0.000551	0.0022	CcSEcCtD
Ranitidine—Confusional state—Bleomycin—lymphatic system cancer	0.000551	0.00219	CcSEcCtD
Ranitidine—Vision blurred—Carmustine—lymphatic system cancer	0.00055	0.00219	CcSEcCtD
Ranitidine—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000549	0.00219	CcSEcCtD
Ranitidine—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.000546	0.00218	CcSEcCtD
Ranitidine—Erythema—Mitoxantrone—lymphatic system cancer	0.000543	0.00216	CcSEcCtD
Ranitidine—Anaemia—Carmustine—lymphatic system cancer	0.00054	0.00215	CcSEcCtD
Ranitidine—Vomiting—Teniposide—lymphatic system cancer	0.000539	0.00215	CcSEcCtD
Ranitidine—Agitation—Carmustine—lymphatic system cancer	0.000537	0.00214	CcSEcCtD
Ranitidine—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000535	0.00213	CcSEcCtD
Ranitidine—Rash—Teniposide—lymphatic system cancer	0.000534	0.00213	CcSEcCtD
Ranitidine—Dermatitis—Teniposide—lymphatic system cancer	0.000534	0.00213	CcSEcCtD
Ranitidine—Headache—Teniposide—lymphatic system cancer	0.000531	0.00212	CcSEcCtD
Ranitidine—Pruritus—Fludarabine—lymphatic system cancer	0.000527	0.0021	CcSEcCtD
Ranitidine—Leukopenia—Carmustine—lymphatic system cancer	0.000523	0.00208	CcSEcCtD
Ranitidine—Anaemia—Vincristine—lymphatic system cancer	0.000515	0.00205	CcSEcCtD
Ranitidine—Agitation—Vincristine—lymphatic system cancer	0.000512	0.00204	CcSEcCtD
Ranitidine—Vision blurred—Mitoxantrone—lymphatic system cancer	0.000512	0.00204	CcSEcCtD
Ranitidine—Photosensitivity—Methotrexate—lymphatic system cancer	0.000512	0.00204	CcSEcCtD
Ranitidine—Hypotension—Bleomycin—lymphatic system cancer	0.00051	0.00203	CcSEcCtD
Ranitidine—Diarrhoea—Fludarabine—lymphatic system cancer	0.00051	0.00203	CcSEcCtD
Ranitidine—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000504	0.00201	CcSEcCtD
Ranitidine—Nausea—Teniposide—lymphatic system cancer	0.000503	0.00201	CcSEcCtD
Ranitidine—Anaemia—Mitoxantrone—lymphatic system cancer	0.000502	0.002	CcSEcCtD
Ranitidine—Vertigo—Vincristine—lymphatic system cancer	0.000501	0.002	CcSEcCtD
Ranitidine—Hepatic failure—Methotrexate—lymphatic system cancer	0.0005	0.00199	CcSEcCtD
Ranitidine—Leukopenia—Vincristine—lymphatic system cancer	0.000499	0.00199	CcSEcCtD
Ranitidine—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000497	0.00198	CcSEcCtD
Ranitidine—Chest pain—Carmustine—lymphatic system cancer	0.000497	0.00198	CcSEcCtD
Ranitidine—Myalgia—Carmustine—lymphatic system cancer	0.000497	0.00198	CcSEcCtD
Ranitidine—Malaise—Mitoxantrone—lymphatic system cancer	0.00049	0.00195	CcSEcCtD
Ranitidine—Dyspnoea—Bleomycin—lymphatic system cancer	0.000487	0.00194	CcSEcCtD
Ranitidine—Leukopenia—Mitoxantrone—lymphatic system cancer	0.000486	0.00194	CcSEcCtD
Ranitidine—Confusional state—Carmustine—lymphatic system cancer	0.000481	0.00192	CcSEcCtD
Ranitidine—Myalgia—Vincristine—lymphatic system cancer	0.000475	0.00189	CcSEcCtD
Ranitidine—Vomiting—Fludarabine—lymphatic system cancer	0.000474	0.00189	CcSEcCtD
Ranitidine—Rash—Fludarabine—lymphatic system cancer	0.00047	0.00187	CcSEcCtD
Ranitidine—Dermatitis—Fludarabine—lymphatic system cancer	0.000469	0.00187	CcSEcCtD
Ranitidine—Pain—Bleomycin—lymphatic system cancer	0.000467	0.00186	CcSEcCtD
Ranitidine—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000467	0.00186	CcSEcCtD
Ranitidine—Headache—Fludarabine—lymphatic system cancer	0.000467	0.00186	CcSEcCtD
Ranitidine—Tachycardia—Carmustine—lymphatic system cancer	0.000465	0.00185	CcSEcCtD
Ranitidine—Myalgia—Mitoxantrone—lymphatic system cancer	0.000462	0.00184	CcSEcCtD
Ranitidine—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000462	0.00184	CcSEcCtD
Ranitidine—Chest pain—Mitoxantrone—lymphatic system cancer	0.000462	0.00184	CcSEcCtD
Ranitidine—Discomfort—Mitoxantrone—lymphatic system cancer	0.000457	0.00182	CcSEcCtD
Ranitidine—Anaphylactic shock—Vincristine—lymphatic system cancer	0.000455	0.00181	CcSEcCtD
Ranitidine—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00045	0.00179	CcSEcCtD
Ranitidine—Confusional state—Mitoxantrone—lymphatic system cancer	0.000447	0.00178	CcSEcCtD
Ranitidine—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000445	0.00178	CcSEcCtD
Ranitidine—Hypotension—Carmustine—lymphatic system cancer	0.000445	0.00178	CcSEcCtD
Ranitidine—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.000443	0.00177	CcSEcCtD
Ranitidine—Nausea—Fludarabine—lymphatic system cancer	0.000442	0.00176	CcSEcCtD
Ranitidine—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00044	0.00175	CcSEcCtD
Ranitidine—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000434	0.00173	CcSEcCtD
Ranitidine—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000434	0.00173	CcSEcCtD
Ranitidine—Urticaria—Bleomycin—lymphatic system cancer	0.000434	0.00173	CcSEcCtD
Ranitidine—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000432	0.00172	CcSEcCtD
Ranitidine—Body temperature increased—Bleomycin—lymphatic system cancer	0.000432	0.00172	CcSEcCtD
Ranitidine—Insomnia—Carmustine—lymphatic system cancer	0.000431	0.00172	CcSEcCtD
Ranitidine—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000428	0.00171	CcSEcCtD
Ranitidine—Hypotension—Vincristine—lymphatic system cancer	0.000425	0.00169	CcSEcCtD
Ranitidine—Dyspnoea—Carmustine—lymphatic system cancer	0.000425	0.00169	CcSEcCtD
Ranitidine—Somnolence—Carmustine—lymphatic system cancer	0.000424	0.00169	CcSEcCtD
Ranitidine—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000415	0.00165	CcSEcCtD
Ranitidine—Hypotension—Mitoxantrone—lymphatic system cancer	0.000414	0.00165	CcSEcCtD
Ranitidine—Insomnia—Vincristine—lymphatic system cancer	0.000412	0.00164	CcSEcCtD
Ranitidine—Pain—Carmustine—lymphatic system cancer	0.000408	0.00162	CcSEcCtD
Ranitidine—Constipation—Carmustine—lymphatic system cancer	0.000408	0.00162	CcSEcCtD
Ranitidine—Breast disorder—Methotrexate—lymphatic system cancer	0.000406	0.00162	CcSEcCtD
Ranitidine—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000404	0.00161	CcSEcCtD
Ranitidine—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000402	0.0016	CcSEcCtD
Ranitidine—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000395	0.00157	CcSEcCtD
Ranitidine—Somnolence—Mitoxantrone—lymphatic system cancer	0.000394	0.00157	CcSEcCtD
Ranitidine—Feeling abnormal—Carmustine—lymphatic system cancer	0.000393	0.00157	CcSEcCtD
Ranitidine—Constipation—Vincristine—lymphatic system cancer	0.000389	0.00155	CcSEcCtD
Ranitidine—Pain—Vincristine—lymphatic system cancer	0.000389	0.00155	CcSEcCtD
Ranitidine—Pruritus—Bleomycin—lymphatic system cancer	0.000386	0.00154	CcSEcCtD
Ranitidine—Eosinophilia—Methotrexate—lymphatic system cancer	0.000384	0.00153	CcSEcCtD
Ranitidine—Pancreatitis—Methotrexate—lymphatic system cancer	0.000381	0.00152	CcSEcCtD
Ranitidine—Pain—Mitoxantrone—lymphatic system cancer	0.000379	0.00151	CcSEcCtD
Ranitidine—Constipation—Mitoxantrone—lymphatic system cancer	0.000379	0.00151	CcSEcCtD
Ranitidine—Abdominal pain—Carmustine—lymphatic system cancer	0.000377	0.0015	CcSEcCtD
Ranitidine—Body temperature increased—Carmustine—lymphatic system cancer	0.000377	0.0015	CcSEcCtD
Ranitidine—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.000372	0.00148	CcSEcCtD
Ranitidine—Pancytopenia—Methotrexate—lymphatic system cancer	0.000369	0.00147	CcSEcCtD
Ranitidine—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000365	0.00146	CcSEcCtD
Ranitidine—Neutropenia—Methotrexate—lymphatic system cancer	0.000363	0.00145	CcSEcCtD
Ranitidine—Abdominal pain—Vincristine—lymphatic system cancer	0.00036	0.00143	CcSEcCtD
Ranitidine—Body temperature increased—Vincristine—lymphatic system cancer	0.00036	0.00143	CcSEcCtD
Ranitidine—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.000358	0.00143	CcSEcCtD
Ranitidine—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.000354	0.00141	CcSEcCtD
Ranitidine—Urticaria—Mitoxantrone—lymphatic system cancer	0.000352	0.0014	CcSEcCtD
Ranitidine—Hypersensitivity—Carmustine—lymphatic system cancer	0.000351	0.0014	CcSEcCtD
Ranitidine—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00035	0.0014	CcSEcCtD
Ranitidine—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00035	0.0014	CcSEcCtD
Ranitidine—Pneumonia—Methotrexate—lymphatic system cancer	0.000348	0.00139	CcSEcCtD
Ranitidine—Vomiting—Bleomycin—lymphatic system cancer	0.000347	0.00138	CcSEcCtD
Ranitidine—Rash—Bleomycin—lymphatic system cancer	0.000344	0.00137	CcSEcCtD
Ranitidine—Dermatitis—Bleomycin—lymphatic system cancer	0.000344	0.00137	CcSEcCtD
Ranitidine—Hypersensitivity—Vincristine—lymphatic system cancer	0.000335	0.00134	CcSEcCtD
Ranitidine—Sweating—Methotrexate—lymphatic system cancer	0.000332	0.00132	CcSEcCtD
Ranitidine—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000326	0.0013	CcSEcCtD
Ranitidine—Diarrhoea—Carmustine—lymphatic system cancer	0.000326	0.0013	CcSEcCtD
Ranitidine—Nausea—Bleomycin—lymphatic system cancer	0.000324	0.00129	CcSEcCtD
Ranitidine—Agranulocytosis—Methotrexate—lymphatic system cancer	0.000323	0.00129	CcSEcCtD
Ranitidine—Dizziness—Carmustine—lymphatic system cancer	0.000315	0.00126	CcSEcCtD
Ranitidine—Diarrhoea—Vincristine—lymphatic system cancer	0.000311	0.00124	CcSEcCtD
Ranitidine—Hepatitis—Methotrexate—lymphatic system cancer	0.000311	0.00124	CcSEcCtD
Ranitidine—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000303	0.00121	CcSEcCtD
Ranitidine—Vomiting—Carmustine—lymphatic system cancer	0.000303	0.00121	CcSEcCtD
Ranitidine—Dizziness—Vincristine—lymphatic system cancer	0.000301	0.0012	CcSEcCtD
Ranitidine—Rash—Carmustine—lymphatic system cancer	0.000301	0.0012	CcSEcCtD
Ranitidine—Dermatitis—Carmustine—lymphatic system cancer	0.0003	0.0012	CcSEcCtD
Ranitidine—Headache—Carmustine—lymphatic system cancer	0.000299	0.00119	CcSEcCtD
Ranitidine—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000294	0.00117	CcSEcCtD
Ranitidine—Vomiting—Vincristine—lymphatic system cancer	0.000289	0.00115	CcSEcCtD
Ranitidine—Rash—Vincristine—lymphatic system cancer	0.000287	0.00114	CcSEcCtD
Ranitidine—Dermatitis—Vincristine—lymphatic system cancer	0.000287	0.00114	CcSEcCtD
Ranitidine—Headache—Vincristine—lymphatic system cancer	0.000285	0.00114	CcSEcCtD
Ranitidine—Nausea—Carmustine—lymphatic system cancer	0.000283	0.00113	CcSEcCtD
Ranitidine—Vomiting—Mitoxantrone—lymphatic system cancer	0.000282	0.00112	CcSEcCtD
Ranitidine—Rash—Mitoxantrone—lymphatic system cancer	0.000279	0.00111	CcSEcCtD
Ranitidine—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000279	0.00111	CcSEcCtD
Ranitidine—Headache—Mitoxantrone—lymphatic system cancer	0.000278	0.00111	CcSEcCtD
Ranitidine—Alopecia—Methotrexate—lymphatic system cancer	0.000275	0.00109	CcSEcCtD
Ranitidine—Erythema—Methotrexate—lymphatic system cancer	0.000271	0.00108	CcSEcCtD
Ranitidine—Nausea—Vincristine—lymphatic system cancer	0.00027	0.00108	CcSEcCtD
Ranitidine—Nausea—Mitoxantrone—lymphatic system cancer	0.000263	0.00105	CcSEcCtD
Ranitidine—Vision blurred—Methotrexate—lymphatic system cancer	0.000255	0.00102	CcSEcCtD
Ranitidine—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000251	0.001	CcSEcCtD
Ranitidine—Anaemia—Methotrexate—lymphatic system cancer	0.00025	0.000997	CcSEcCtD
Ranitidine—Malaise—Methotrexate—lymphatic system cancer	0.000244	0.000972	CcSEcCtD
Ranitidine—Vertigo—Methotrexate—lymphatic system cancer	0.000243	0.000969	CcSEcCtD
Ranitidine—Leukopenia—Methotrexate—lymphatic system cancer	0.000242	0.000965	CcSEcCtD
Ranitidine—Arthralgia—Methotrexate—lymphatic system cancer	0.00023	0.000918	CcSEcCtD
Ranitidine—Myalgia—Methotrexate—lymphatic system cancer	0.00023	0.000918	CcSEcCtD
Ranitidine—Chest pain—Methotrexate—lymphatic system cancer	0.00023	0.000918	CcSEcCtD
Ranitidine—Discomfort—Methotrexate—lymphatic system cancer	0.000228	0.000907	CcSEcCtD
Ranitidine—Confusional state—Methotrexate—lymphatic system cancer	0.000223	0.000887	CcSEcCtD
Ranitidine—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000221	0.00088	CcSEcCtD
Ranitidine—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000216	0.000862	CcSEcCtD
Ranitidine—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000213	0.000851	CcSEcCtD
Ranitidine—Hypotension—Methotrexate—lymphatic system cancer	0.000206	0.000822	CcSEcCtD
Ranitidine—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000201	0.000802	CcSEcCtD
Ranitidine—Insomnia—Methotrexate—lymphatic system cancer	0.0002	0.000796	CcSEcCtD
Ranitidine—Dyspnoea—Methotrexate—lymphatic system cancer	0.000197	0.000785	CcSEcCtD
Ranitidine—Somnolence—Methotrexate—lymphatic system cancer	0.000196	0.000782	CcSEcCtD
Ranitidine—Pain—Methotrexate—lymphatic system cancer	0.000189	0.000753	CcSEcCtD
Ranitidine—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000182	0.000725	CcSEcCtD
Ranitidine—Urticaria—Methotrexate—lymphatic system cancer	0.000175	0.000699	CcSEcCtD
Ranitidine—Body temperature increased—Methotrexate—lymphatic system cancer	0.000175	0.000696	CcSEcCtD
Ranitidine—Abdominal pain—Methotrexate—lymphatic system cancer	0.000175	0.000696	CcSEcCtD
Ranitidine—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000163	0.000648	CcSEcCtD
Ranitidine—Pruritus—Methotrexate—lymphatic system cancer	0.000156	0.000623	CcSEcCtD
Ranitidine—Diarrhoea—Methotrexate—lymphatic system cancer	0.000151	0.000602	CcSEcCtD
Ranitidine—Dizziness—Methotrexate—lymphatic system cancer	0.000146	0.000582	CcSEcCtD
Ranitidine—Vomiting—Methotrexate—lymphatic system cancer	0.00014	0.000559	CcSEcCtD
Ranitidine—Rash—Methotrexate—lymphatic system cancer	0.000139	0.000555	CcSEcCtD
Ranitidine—Dermatitis—Methotrexate—lymphatic system cancer	0.000139	0.000554	CcSEcCtD
Ranitidine—Headache—Methotrexate—lymphatic system cancer	0.000138	0.000551	CcSEcCtD
Ranitidine—Nausea—Methotrexate—lymphatic system cancer	0.000131	0.000523	CcSEcCtD
